• Explore /
  • Poster
  • / PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.

PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.

Abstract Poster

Authors

null

Christian Kurzeder

Kliniken Essen Mitte, Essen, Germany

Christian Kurzeder , Jose Maria Del Campo , Patricia Pautier , Felix Hilpert , Angiolo Gadducci , Petronella Ottevanger , Domenica Lorusso , Ignace Vergote , Isabel Bover , Michel Fabbro , Frederik Marmé , Yolanda Garcia , Frédéric Selle , Martina Gropp-Meier , Beatriz Pardo , Ulrich Freudensprung , Ru-Amir Walker , Antonio Gonzalez-Martin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01684878

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5613)

DOI

10.1200/jco.2014.32.15_suppl.tps5613

Abstract #

TPS5613

Poster Bd #

394A

Abstract Disclosures

Similar Posters

First Author: Antonio Gonzalez-Martin

First Author: Thomas J. Herzog

First Author: Kathleen N. Moore

First Author: Jalid Sehouli